Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerSolange Peters, Tony Mok, D. Ross Camidge et al.|New England Journal of Medicine|2017Cited by 2.4k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James Chih‐Hsin Yang, Yi‐Long Wu, Chong‐Jen Yu et al.|The Lancet Oncology|2015Cited by 980
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 393
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Erica Evans, Justin F. Gainor et al.|Cancer Discovery|2018Cited by 392
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Shun Lu et al.|New England Journal of Medicine|2024Cited by 369